A new combination of antibiotics allows treating 60% of hospital-acquired pneumonia

A study published in the journal The Lancet Infectious Diseases shows the ability of a new antibiotic (ceftazimida-avibactam) to treat hospital-acquired pneumonia, including ventilation-associated pneumonia. It has similar efficacy to one of the most used type of antibiotics in the treatment of this infection, carbapenems, but has the advantage of overcoming problems derived from its administration, such as the resistance of certain bacteria. Dr. Antoni Torres, Head of the Respiratory Intensive Surveillance Unit (UVIR) of the Hospital Clínic and head of the IDIBAPS team on Applied research in infectious respiratory diseases, critically ill patients and lung cancer, is the principal investigator of the study and first author of the article.